Read More

Nanobiotix Announces Presentation Of The Final Efficacy Analysis From Phase 1 Cohort Expansion Evaluating NBTXR3 In Locally Advanced Head And Neck Cancer Showing Median Progression-Free Survival Of 16.9 Months And Median Overall Survival Of 23.1 Months

Final data from Study 102 Dose Expansion show that radiotherapy-activated NBTXR3 was feasible and well tolerated in elderly patients with a high burden of comorbidity (n=56)Consistently high injected-lesion overall